Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Kevin Grogan
Bayer's pharma president and board member Dieter Weinand talks to Scrip about the importance of big picture thinking when weighing the value of innovative drugs to healthcare systems, the revolutionary potential of big data and how "transparency and open dialogue will further enhance the understanding of our business."
The departure of finance chief Simone Menne follows "divergent views" with the board over strategy shows that Boehringer Ingelheim will not countenance any moves that could threaten its independence.
Jane Griffiths tells Scrip that rather than reducing Actelion's reliance on PAH, there is still a lot to do in looking at different mechanisms and pathways for the disease and being under the J&J umbrella can only help.
The UK group has raised nearly $320m this week which will be used to build commercial organizations in the US and Europe ahead of potential approvals for its cannabinoid epilepsy therapy Epidiolex.
The company has linked up with Rani Therapeutics to develop a simple-to-swallow capsule that is able to provide an alternative to current injectable therapies for hemophilia A.
Idorsia, the Swiss company spun out of Actelion after the latter was bought by J&J, is to get another windfall from the US major which has triggered an option to co-develop the Phase III-ready drug aprocitentan.